ASBP Stock Chart & Stats
$0.27
--
Market closed
$0.27
--
Day’s Range― - ―
52-Week Range$3.30 - $1,050.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)27.58M
Market Cap
$7.77M
Enterprise Value-$4.62M
Total Cash (Recent Filing)$5.86M
Total Debt (Recent Filing)$499.21K
Price to Earnings (P/E)―
Beta1.66
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.41
Shares Outstanding1,295,234
10 Day Avg. Volume3,584,512
30 Day Avg. Volume27,577,381
Financial Highlights & Ratios
PEG Ratio0.98
Price to Book (P/B)-37.14
Price to Sales (P/S)38181.40
P/FCF Ratio-48.10
Enterprise Value/Market Cap-0.60
Enterprise Value/Revenue-133.82
Enterprise Value/Gross Profit-820.74
Enterprise Value/Ebitda-1.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Aspire Biopharma Holdings News
ASBP FAQ
What was Aspire Biopharma Holdings’s price range in the past 12 months?
Aspire Biopharma Holdings lowest stock price was $3.30 and its highest was $1050.00 in the past 12 months.
What is Aspire Biopharma Holdings’s market cap?
Aspire Biopharma Holdings’s market cap is $7.77M.
When is Aspire Biopharma Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Aspire Biopharma Holdings’s earnings last quarter?
Currently, no data Available
Is Aspire Biopharma Holdings overvalued?
According to Wall Street analysts Aspire Biopharma Holdings’s price is currently Overvalued.
Does Aspire Biopharma Holdings pay dividends?
Aspire Biopharma Holdings does not currently pay dividends.
What is Aspire Biopharma Holdings’s EPS estimate?
Aspire Biopharma Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aspire Biopharma Holdings have?
Aspire Biopharma Holdings has 1,295,234 shares outstanding.
What happened to Aspire Biopharma Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aspire Biopharma Holdings?
Currently, no hedge funds are holding shares in ASBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aspire Biopharma Holdings
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
Technical Analysis
Ownership Overview
― Insiders
0.79% Mutual Funds
― Other Institutional Investors
99.19% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---